NASDAQ:CRSP - Crispr Therapeutics Stock Price, Forecast & News

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRSP shares have decreased by 3.4% and is now trading at $41.82. View which stocks have been mosted impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics.

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Crispr Therapeutics.

Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Wednesday, February, 12th. The company reported $0.51 EPS for the quarter, beating the Zacks' consensus estimate of ($0.68) by $1.19. The firm had revenue of $77 million for the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The firm's revenue for the quarter was up 76900.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.92) EPS. View Crispr Therapeutics' earnings history.

16 equities research analysts have issued 12 month price targets for Crispr Therapeutics' stock. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' share price to reach $74.42 in the next year. This suggests a possible upside of 78.0% from the stock's current price. View analysts' price targets for Crispr Therapeutics.

Press coverage about CRSP stock has trended somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Crispr Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCrispr Therapeutics.

Crispr Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,305,800 shares, an increase of 5.3% from the February 27th total of 3,140,000 shares. Based on an average trading volume of 906,900 shares, the days-to-cover ratio is currently 3.6 days. Currently, 12.5% of the shares of the company are short sold. View Crispr Therapeutics' Current Options Chain.

Some companies that are related to Crispr Therapeutics include Qiagen (QGEN), Moderna (MRNA), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT), Audentes Therapeutics (BOLD) and bluebird bio (BLUE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), Micron Technology (MU), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Sangamo Therapeutics (SGMO), Intel (INTC) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Crispr Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (7.62%), Nikko Asset Management Americas Inc. (5.52%), ARK Investment Management LLC (5.36%), FMR LLC (1.73%), Credit Suisse AG (1.31%) and Abingworth LLP (0.94%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View institutional ownership trends for Crispr Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Abingworth LLP, Lord Abbett & CO. LLC, Bank of America Corp DE, Versant Venture Management LLC, SG Americas Securities LLC, Barclays PLC, and Credit Suisse AG. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, and Samarth Kulkarni. View insider buying and selling activity for Crispr Therapeutics.

CRSP stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Nikko Asset Management Americas Inc., Capital International Investors, ARK Investment Management LLC, Laurion Capital Management LP, Columbus Circle Investors, and Hodges Capital Management Inc.. View insider buying and selling activity for Crispr Therapeutics.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRSP stock can currently be purchased for approximately $41.82.

Crispr Therapeutics has a market capitalization of $2.54 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe. View additional information about Crispr Therapeutics.

The official website for Crispr Therapeutics is http://www.crisprtx.com/.

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]